Insights from Portuguese Nephrologists and Rheumatologists Concerning the Treatment of ANCA Vasculitis
DOI:
https://doi.org/10.20344/amp.21635Keywords:
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy, Nephrologists, Practice Patterns, Physicians, RheumatologistsAbstract
Introduction: Antineutrophilic cytoplasmic antibodies-associated vasculitis (AAV) encompasses granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. These rare diseases are characterized by an exaggerated immune response in blood vessels, leading to inflammation, vascular injury, ischemia, and necrosis of affected tissues and organs. Despite the existence of European recommendations for treating AAV, their implementation in Portugal remains unclear.
Methods: To address this gap, an online Delphi panel was conducted involving 55 Portuguese nephrologists and rheumatologists, representing the main specialties involved in the management of AAV. The primary objective was to assess the level of consensus regarding the treatment of AAV in Portugal and the application of European recommendations in daily clinical practice. The specialists evaluated 29 statements formulated by a group of Portuguese experts with extensive experience in AAV, addressing key aspects of AAV management, rated on a 4-point Likert scale. Consensus was defined as > 70% of responses either strongly agreeing or strongly disagreeing with a statement, while the majority level required > 70% agreement or disagreement.
Results: After one round, no statement reached consensus globally, and eight out of the 29 statements did not achieve a qualified majority. Nonetheless, this study demonstrates a high level of agreement within each medical specialty, due to the distinct characteristics of the patient populations treated by each specialty. While the results suggest partial adherence to European recommendations, they also highlight the need to standardize clinical practices for AAV treatment in Portugal.
Conclusion: This study underscores the importance of aligning national practices with established European recommendations to ensure the best outcomes for patients with AAV.
Downloads
References
Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, et al. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med. 2007;120:643 e9-14.
Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187-92.
Watts RA, Mahr A, Mohammad AJ, Gatenby P, Basu N, Flores-Suarez LF. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015;30:i14-22.
Ntatsaki E, Watts RA, Scott DG. Epidemiology of ANCA-associated vasculitis. Rheum Dis Clin North Am. 2010;36:447-61.
Jennette JC, Falk RJ. Small-vessel vasculitis. review-article. N Engl J Med. 1997;337:1512-23.
Kitching AR, Anders HJ, Basu N, Brouwer E, Gordon J, Jayne DR, et al. ANCA-associated vasculitis. ReviewPaper. Nat Rev Dis Primers. 2020;6:71.
Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87:671-8.
Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827-32.
Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40:371-80.
Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, et al. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007;66:283-92.
Miller A, Basu N, Luqmani R. Assessment of systemic vasculitis. Autoimmun Rev. 2008;8:170-5.
Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCAassociated vasculitis. Ann Rheum Dis. 2016;75:1583-94.
Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310-7.
Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, et al. EULAR recommendations for the management of ANCAassociated vasculitis: 2022 update. Ann Rheum Dis. 2024;83:30-47.
Geetha D, Jin Q, Scott J, Hruskova Z, Hanouneh M, Little MA, et al. Comparisons of guidelines and recommendations on managing antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep. 2018;3:1039-49.
Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66:605-17.
Sharma P, Sharma S, Baltaro R, Hurley J. Systemic vasculitis. Am Fam Physician. 2011;83:556-65.
Bekker P, Dairaghi D, Seitz L, Leleti M, Wang Y, Ertl L, et al. Characterization of pharmacologic and pharmacokinetic properties of ccx168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study. PLoS One. 2016;11:e0164646.
Jayne DR, Merkel PA, Schall TJ, Bekker P, Group AS. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599-609.
Gabilan C, Pfirmann P, Ribes D, Rigothier C, Chauveau D, Casemayou A, et al. Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: a steroid-sparing option. Kidney Int Rep. 2022;7:1115-8.
van Leeuwen JR, Bredewold OW, van Dam LS, Werkman SL, Jonker JT, Geelhoed M, et al. Compassionate use of avacopan in difficult-totreat antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep. 2022;7:624-8.
Schirmer J, Sanchez-Alamo B, Monti S, Hellmich B, Jayne D. Pos0830 Systematic literature review informing the 2022 update of the eular recommendations for the management of ancaassociated vasculitis: focus on treatment strategies. Ann Rheum Dis. 2022;81:s706.1-706.
Turgeon D, Bakowsky V, Baldwin C, Cabral DA, Clements-Baker M, Clifford A, et al. CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum. Rheumatology. 2023;62:2646-51.
Ntatsaki E, Carruthers D, Chakravarty K, D’Cruz D, Harper L, Jayne D, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology. 2014;53:2306-9.
de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670-80.
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221-32.
Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. research-article. N Engl J Med. 2014;371:1771-80.
Charles P, Terrier B, Perrodeau E, Cohen P, Faguer S, Huart A, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77:1143-9.
Smith RM, Jones RB, Specks U, Bond S, Nodale M, Aljayyousi R, et al. Rituximab as therapy to induce remission after relapse in ANCAassociated vasculitis. Ann Rheum Dis. 2020;79:1243-9.
Morris A, Geetha D. PEXIVAS challenges current ANCA-associated vasculitis therapy. Nat Rev Nephrol. 2020;16:373-4.
McGovern D, Williams SP, Parsons K, Farrah TE, Gallacher PJ, Miller-Hodges E, et al. Long-term outcomes in elderly patients with ANCAassociated vasculitis. Rheumatology. 2020;59:1076-83.
Quintana LF, Kronbichler A, Blasco M, Zhao MH, Jayne D. ANCA associated vasculitis: the journey to complement-targeted therapies. Mol Immunol. 2019;112:394-8.
McClure M, Jones RB. Treatment of relapses in ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2019;14:967-9.
Kant S, Azar A, Gapud EJ, Antiochos B, Manno R, Seo P, et al. Subcutaneous Immunoglobulin for antibody deficiency in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Cureus. 2019;11:e6367.
Crickx E, Machelart I, Lazaro E, Kahn JE, Cohen-Aubart F, Martin T, et al. Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vasculitides: a french nationwide study of ninety-two patients. Arthritis Rheumatol. 2016;68:702-12.
Shimizu T, Morita T, Kumanogoh A. The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibodyassociated vasculitis: a meta-analysis. Rheumatology. 2020;59:959-67.
Molnar A, Studinger P, Ledo N. Diagnostic and therapeutic approach in ANCA-associated glomerulonephritis: a review on management strategies. Front Med. 2022;9:884188.
Yuen SJ, Rubin PA. Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. Arch Ophthalmol. 2003;121:491-9.
King C, Harper L. Avoidance of harm from treatment for ANCAassociated vasculitis. Curr Treatm Opt Rheumatol. 2017;3:230-43.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
